Quality of life · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower event‐free survival (reported as relapse, progressive disease,… compared with standard therapy (moderate certainty).
1 finding from 1 review
Early toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Late non‐haematological toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of clinical tumour lysis syndrome · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: urate oxidase showed no clear difference in incidence of clinical tumour lysis syndrome ( compared with allopurinol (low certainty).
1 finding from 1 review
Organ system failure ‐ Renal insufficiency leading to replacement therapy · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
Serum urate normalisation ‐ not reported · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: high‐dose urate oxidase showed no clear difference in normalisation of serum uric acid ( compared with low‐dose urate oxidase (low certainty).
1 finding from 1 review
Percentage reduction in serum uric acid level · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
AUC of serum uric acid level · children with haematological malignancy at risk of tumour lysis syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: high‐dose urate oxidase showed no clear difference in frequency of adverse events ( compared with low‐dose urate oxidase (low certainty).
1 finding from 1 review
Mortality due to tumour lysis syndrome · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: urate oxidase may leads to lower mortality due to tumour lysis syndrome ( compared with allopurinol (low certainty).
1 finding from 1 review
Organ system failure ‐ Renal insufficiency leading to replacement therapy · children with haematological malignancy at risk of tumour lysis syndrome
It is very uncertain whether summary of findings: urate oxidase changes renal failure requiring renal replacement therapy ( compared with allopurinol (very low certainty).
1 finding from 1 review
Serum urate normalisation ‐ not reported · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
Percentage reduction in serum uric acid level · children with haematological malignancy at risk of tumour lysis syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
AUC of serum uric acid level · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
Frequency of adverse events ( · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: urate oxidase may leads to higher frequency of adverse events ( compared with allopurinol (low certainty).
1 finding from 1 review